PFO
UTHR icon

Pathstone Family Office’s United Therapeutics UTHR Stock Holding History

Pathstone Family Office’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$369K Buy
+1,635
New +$377K ﹤0.01% 1195
2023
Q1 		– Sell
-1,479
Closed -$231K – 1372
2022
Q4 		$231K Buy
+1,479
New +$373K ﹤0.01% 1032

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Pathstone Family Office's UTHR Position: Q3 2023 in Review

Pathstone Family Office opened a new position in United Therapeutics (UTHR) in Q3 2023: 1,635 shares worth $369K. The stake represents ﹤0.01% of the portfolio and ranks #1195 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in UTHR as recently as Q4 2022.

Pathstone Family Office first reported a position in UTHR in Q4 2022 and has held it in 2 quarters since. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

  • Pathstone Family Office held 1,635 shares of United Therapeutics worth $369K as of Q3 2023.
  • United Therapeutics was a new Pathstone Family Office position in Q3 2023.
  • United Therapeutics made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1195 holding.
  • Pathstone Family Office first reported a position in United Therapeutics in Q4 2022 and has held it in 2 quarters since.
  • 508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.